Edition:
United States

Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

1.43USD
16 Feb 2018
Change (% chg)

$-0.04 (-2.72%)
Prev Close
$1.47
Open
$1.47
Day's High
$1.49
Day's Low
$1.42
Volume
56,382
Avg. Vol
37,354
52-wk High
$10.80
52-wk Low
$1.38

Chart for

About

Altimmune, Inc., formerly Pharmathene, Inc., is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies,... (more)

Overall

Beta: 2.57
Market Cap(Mil.): $22.85
Shares Outstanding(Mil.): 15.65
Dividend: 29.10
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Hudson Bay Capital Management Reports A 9.99 Percent Passive Stake In Altimmune

* HUDSON BAY CAPITAL MANAGEMENT LP‍ REPORTS A 9.99 PERCENT PASSIVE STAKE IN ALTIMMUNE, INC​ AS OF DECEMBER 31, 2017 - SEC FILING Source text for Eikon: [http://bit.ly/2nwUAiB] Further company coverage:

Feb 02 2018

BRIEF-Altimmune Announces Allowance On Patent Covering Use Of Nasoshield In U.S.

* ALTIMMUNE ANNOUNCES NOTICE OF ALLOWANCE ON PATENT COVERING USE OF NASOSHIELD IN THE U.S. Source text for Eikon: Further company coverage:

Jan 23 2018

BRIEF-Altimmune Elects Mitchel Sayare As Chairman Of Its Board

* ALTIMMUNE ELECTS MITCHEL SAYARE, PH.D. AS CHAIRMAN OF ITS BOARD OF DIRECTORS

Jan 03 2018

BRIEF-Altimmune reports Q3 loss per share $2.05

* Altimmune announces third quarter 2017 financial results and provides corporate update

Nov 09 2017

BRIEF-Altimmune to provide corporate update at Rodman & Renshaw global investment conference

* Altimmune to provide corporate update at the Rodman & Renshaw global investment conference Source text for Eikon: Further company coverage:

Sep 06 2017

BRIEF-Altimmune submits investigational new drug application for Nasovax for phase 2 trial preparation

* Altimmune submits investigational new drug application for Nasovax in preparation for Phase 2 trial

Aug 21 2017

Competitors

  Price Chg
Green Cross Corp (006280.KS) ₩204,000.00 +4,500.00
Pfizer Inc. (PFE.N) $36.26 +0.55
Panacea Biotec Limited (PNCA.NS) Rs327.45 -23.45
Bavarian Nordic A/S (BAVA.CO) kr.244.80 +5.00
Emergent Biosolutions Inc (EBS.N) $49.96 +0.79
Ibio Inc (IBIO.A) $0.19 -0.01
Soligenix Inc (SNGX.OQ) $2.07 +0.05
Pfenex Inc (PFNX.A) $3.45 0.00

Earnings vs. Estimates